Literature DB >> 31277733

Postchemotherapy Resection of Residual Mass in Nonseminomatous Germ Cell Tumor.

Saum Ghodoussipour1, Siamak Daneshmand2.   

Abstract

The introduction of cisplatin-based chemotherapy has revolutionized the care of patients with disseminated testicular germ cell tumors. Although a majority are cured with chemotherapy alone, surgical resection continues to play a role because one-third will have residual mass after chemotherapy. In this article, we review the current indications for postchemotherapy resection in nonseminomatous germ cell tumors, including masses greater than 1 cm, resection after salvage chemotherapy, with elevated markers, after late relapse, and for growing teratoma syndrome. We also highlight technical considerations of this often-challenging surgery, including the need for adjunctive procedures, extraretroperitoneal resections, and modern techniques to minimize morbidity.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Germ cell tumor; Nonseminomatous; Retroperitoneal lymph node dissection; Testicular cancer

Mesh:

Substances:

Year:  2019        PMID: 31277733     DOI: 10.1016/j.ucl.2019.04.004

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  3 in total

Review 1.  Surgical strategies for postchemotherapy testis cancer.

Authors:  Saum Ghodoussipour; Siamak Daneshmand
Journal:  Transl Androl Urol       Date:  2020-01

2.  Re: Lloyd P, Hong A, Furrer MA, et al. A comparative study of perioperative outcomes for 100 consecutive post-chemotherapy and primary robot assisted and open retroperitoneal lymph node dissections. World J Urol. 2021; DOI: 10.1007/s00345-021-03832-0.

Authors:  Alireza Ghoreifi; Hooman Djaladat
Journal:  World J Urol       Date:  2022-01-22       Impact factor: 4.226

Review 3.  Between a Rock and a Hard Place: An Epigenetic-Centric View of Testicular Germ Cell Tumors.

Authors:  Ratnakar Singh; Zeeshan Fazal; Sarah J Freemantle; Michael J Spinella
Journal:  Cancers (Basel)       Date:  2021-03-25       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.